Naringenin Nanoparticles and Their Effects on Liver Cancer
Author Information
Author(s): Aya G. Elwan, Tarek M. Mohamed, Doha M. Beltagy, Doaa M. El Gamal
Primary Institution: Tanta University
Hypothesis
Can naringenin nanoparticles enhance the anticancer effects of naringenin in hepatocellular carcinoma cells?
Conclusion
Naringenin nanoparticles effectively inhibit cell proliferation and induce apoptosis in human hepatocellular carcinoma cells without harming normal cells.
Supporting Evidence
- Naringenin nanoparticles showed a significant reduction in cell viability in HepG2 cells.
- NARNPs induced late apoptosis in 56.1% of HepG2 cells.
- NARNPs had no cytotoxic effect on WI38 cells, with 97% viability after treatment.
- The IC50 values were determined as 22.32 µg/ml for naringenin, 1.6 µg/ml for NARNPs, and 0.46 µg/ml for doxorubicin.
- NARNPs enhanced the cytotoxic effect of doxorubicin in HepG2 cells.
- NARNPs induced cell cycle arrest in the Go/G1 and G2/M phases in HepG2 cells.
- Increased expression of apoptotic proteins was observed in HepG2 cells treated with NARNPs.
Takeaway
Naringenin nanoparticles can help fight liver cancer by making cancer cells die while leaving healthy cells alone.
Methodology
Naringenin nanoparticles were prepared and their anticancer effects were tested on HepG2 and WI38 cell lines using various assays including MTT and flow cytometry.
Limitations
The study primarily focused on in vitro models, which may not fully represent in vivo conditions.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website